AbbVie reports successful study data and new regulatory decisions
AbbVie announced successful completion of phase trials and new regulatory decisions between Sept. 30 and Oct. 13, 2026.
Key points
- Temab‑A received two FDA breakthrough therapy designations for colorectal cancer and non‑small cell lung cancer.
- The positive data involve patients with atopic dermatitis, non‑segmental vitiligo, colorectal and non‑small cell lung cancer, and Crohn’s disease.
- EU approval of RINVOQ and FDA breakthrough therapy designations for Temab‑A confirm regulators’ positive view of safety and efficacy potential.
What happened
Temab‑A received two FDA breakthrough therapy designations for colorectal cancer and non‑small cell lung cancer.
Who is affected
The positive data involve patients with atopic dermatitis, non‑segmental vitiligo, colorectal and non‑small cell lung cancer, and Crohn’s disease.
Evidence assessment
EU approval of RINVOQ and FDA breakthrough therapy designations for Temab‑A confirm regulators’ positive view of safety and efficacy potential.
Next steps
The announcements gave no specific dates for further steps; the company did not disclose when it will file approval applications or start additional studies.
Original sources
- AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
- AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow AbbVie
A notification in your browser or on your phone when we publish about AbbVie. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
